Skip to contentA
Anika Therapeutics, Inc.
A
ANIKAnika Therapeutics, Inc. Q3 2023 · 10-Q
Revenue$41.47M$41.47M+3.0% vs Q3 2022 Net Income-$6.58M-$6.58MN/M vs Q3 2022 EPS Diluted-$0.45-$0.45N/M vs Q3 2022 Gross Profit$24,944,000+9.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Anika Therapeutics, Inc. · CIK 898437 · Engraved from SEC EDGAR
Operating Cash Flowderived$6,485,000+139.4% Free Cash Flowderived$5,744,000+464.2% Margins · derivedGross margin60.2%+3.6 pt vs Q3 2022
Operating margin-18.5%−4.1 pt vs Q3 2022
Net margin-15.9%−5.5 pt vs Q3 2022
ended Sep 30, 2023 · filed Nov 3, 2023 · 34 d after period end